Impact of Timing of Concurrent Chemoradiation for Newly Diagnosed Glioblastoma

A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma

(2014) J. L. Clarke et al.   NEURO-ONCOLOGY

Waiting times before initiation of radiotherapy might not affect outcomes for patients with glioblastoma: a French retrospective analysis of patients treated in the era of concomitant temozolomide and radiotherapy

(2012) Georges Noel et al.   JOURNAL OF NEURO-ONCOLOGY

The timing of cranial radiation in elderly patients with newly diagnosed glioblastoma multiforme

(2011) R. Lai et al.   NEURO-ONCOLOGY

Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma

(2011) N. Butowski et al.   NEURO-ONCOLOGY

partDSA: deletion/substitution/addition algorithm for partitioning the covariate space in prediction

(2010) Annette M. Molinaro et al.   BIOINFORMATICS

Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: A phase I study

(2010) N. Butowski et al.   NEURO-ONCOLOGY

A mathematical model of brain tumour response to radiotherapy and chemotherapy considering radiobiological aspects

(2009) Lara Barazzuol et al.   JOURNAL OF THEORETICAL BIOLOGY

Short Delay in Initiation of Radiotherapy May Not Affect Outcome of Patients With Glioblastoma: A Secondary Analysis From the Radiation Therapy Oncology Group Database

(2008) Deborah T. Blumenthal et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Study of Erlotinib Plus Temozolomide During and After Radiation Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

(2008) Michael D. Prados et al.   JOURNAL OF CLINICAL ONCOLOGY